Clinical trials involving thousands of patients have established the utility of defined antibodies that detect ER and PR, as well as HER2 in tissue sections of patients' breast cancers using appropriate endpoints, thus enabling the identification of patients likely to benefit from endocrine or Herceptin therapy. The gene discussed is ERBB2; the disease is breast cancer.